RxDoctor Payments Data

Ann Hassell

Family · North Charleston, SCNPI 1487373536

Payments from drug & device makers

$844in general payments, 2019–2025

Across 32 payments — averaging $26.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Calliditas Therapeutics US Inc.$210
  • Amgen$86
  • Aurinia Pharma U.S., Inc.$54
  • Novo Nordisk$53
  • Vifor Pharma, Inc.$51
  • Mallinckrodt Hospital Products Inc.$49
  • plus $341 from 11 others

What the payments were for

  • Food & beverage$844100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$844 in reported general payments places this provider in the 60th percentile of 3,248 family providers in South Carolina.

See all family providers in South Carolina

Medicare billing

Part B allowed, 2024
$50,609
Medicare patients
245
Services billed
926

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Sevelamer Carbonate67$18,725
VeltassaPatiromer Calcium Sorbitex29$15,510
LokelmaSodium Zirconium Cyclosilicate11$5,960
FarxigaDapagliflozin Propanediol11$5,536
ClinisolParenteral Amino Acid 15% No.516$3,254
Calcium Acetate19$2,035
Nebivolol Hcl11$1,417
Midodrine Hcl17$513
Doxazosin Mesylate36$266
Carvedilol59$251
Amlodipine Besylate30$191
Losartan Potassium16$181
Lidocaine-PrilocaineLidocaine/Prilocaine11$179
Potassium Chloride17$177
Hydralazine Hcl16$113

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaLokelma, Farxiga$37$11,49622 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 3,248 family providers in South Carolina.

Other family in North Charleston

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →